FDA approves Viagra ingredient for pulmonary hypertension

Share this article:
The FDA has approved sildenafil citrate, the active ingredient in Viagra, to treat pulmonary hypertension, Pfizer said yesterday.
The compound will be called Revatio and will be sold in a 20 mg pill that is white and round to distinguish it from Viagra's blue diamond-shaped pill for erectile dysfunction sold in 25,50 or 100 mg dosages. Pfizer expects Revatio to be available in retail pharmacies in mid-July.
Pulmonary arterial hypertension is a rare, aggressive and life-shortening vascular disease characterized by dangerously high pressure in the blood vessels that lead from the heart to the lungs.  It is estimated to affect approximately 100,000 people worldwide.
The new application may add several hundred million dollars to Viagra sales, which were $1.68 billion last year, SunTrust Robinson Humphrey analyst Bert Hazlett told Bloomberg News.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.